-Steven A Narod Researcher Activity Profile

Research Author Detailed Information 

Steven A Narod Publication Rate By Year

Steven A Narod has published 1 paper(s) in 1989, 1 paper(s) in 2006, 21 paper(s) in 2007, 8 paper(s) in 2008, for a total of 31 research publications in total.

Steven A Sa Narod Author Information

LAST NAME: narod

FIRST NAME: Steven A

INITIALS: sa

AFFILIATION:

Papers

Steven A Narod's Publication Record

1. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Year Published: 2007
Sam Minuk Cancer Genetics and Biomarker Laboratories, Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada.
2. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. Year Published: 2006
Department of Epidemiology and Public Health, Yale University School of Medicine, 60 College St., PO Box 208034, New Haven, CT 06520-8034, USA. harvey.risch@yale.edu
3. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Year Published: 2007
Samuel Lunenfeld Research Institute, Toronto, ON, Canada.
4. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Year Published: 2007
Department of Radiation Oncology, Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada.
5. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Year Published: 2007
Lawrence Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada M5T 1P8. kelly.metcalfe@utoronto.ca
6. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Year Published: 2007
Centre for Research in Women's Health, Women's College Hospital, University of Toronto, Room 750, 790 Bay Street, 7th Floor, Toronto, ON M5G 1N8, Canada.
7. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Year Published: 2007
Department of Radiation Oncology, Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada.
8. CYP1B1 and predisposition to breast cancer in Poland. Year Published: 2007
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
9. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Year Published: 2007
Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK. antonis@srl.cam.ac.uk
10. BARD1 and breast cancer in Poland. Year Published: 2007
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, ul. Po?abska 4, 70-115, Szczecin, Poland, aniaj@sci.pam.szczecin.pl.
11. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Year Published: 2007
1Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
12. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Year Published: 2007
Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK. antonis@srl.cam.ac.uk
13. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Year Published: 2007
Department of Radiation Oncology, Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada.
14. BRCA1 mutations and prostate cancer in Poland. Year Published: 2007
Department of Genetics and Pathology, International Hereditary Cancer Center, Poland. cezarycy@sci.pam.szczecin.pl
15. Is CHEK2 a cause of the Li-Fraumeni syndrome? Year Published: 2008
16. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Year Published: 2007
Centre for Research in Women's Health, Women's College Hospital, University of Toronto, Room 750, 790 Bay Street, 7th Floor, Toronto, ON M5G 1N8, Canada.
17. CYP1B1 and predisposition to breast cancer in Poland. Year Published: 2007
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
18. BRCA1 mutations and prostate cancer in Poland. Year Published: 2007
Department of Genetics and Pathology, International Hereditary Cancer Center, Poland. cezarycy@sci.pam.szczecin.pl
19. Is CHEK2 a cause of the Li-Fraumeni syndrome? Year Published: 2008
20. CYP1B1 and predisposition to breast cancer in Poland. Year Published: 2007
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
21. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Year Published: 2007
Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. robert.nam@utoronto.ca
22. Spontaneous abortions in Ontario, 1979 to 1984. Year Published: 1989
23. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Year Published: 2007
Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. robert.nam@utoronto.ca
24. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Year Published: 2008
Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, 546 Pine Ave West, Montréal, QC, Canada H2W 1S6. William.foulkes@mcgill.ca.
25. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Year Published: 2008
Digestive Disease Research Center, Medical Sciences/University of Tehran, Tehran, Iran.
26. Mutation screening using fluorescence multiplex denaturing gradient gel electrophoresis (FMD): detecting mutations in the BRCA1 gene. Year Published: 2007
The Centre for Research in Women's Health, University of Toronto, 790 Bay Street, Toronto, Ontario, M5G IN8, Canada.
27. The risk of developing uterine sarcoma after tamoxifen use. Year Published: 2008
Department of Obstetrics & Gynecology, Division of Gynecology & Oncology, Carmel Medical Center, Haifa, Israel. olavie@zahav.net.il
28. Triple-negative breast cancer: clinical features and patterns of recurrence. Year Published: 2007
Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada.
29. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Year Published: 2008
Women's College Research Institute, University Health Network, University of Toronto, Canada.
30. Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Year Published: 2008
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, ul. Po?abska 4, 70-115 Szczecin, Poland. cezarycy@sci.pam.szczecin.pl
31. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Year Published: 2008
Women's College Research Institute, University Health Network, University of Toronto, Canada.